Skip to content
- SHIFT – use of Ivabradine to reduce heart rate in CHF
- SMART – use of balanced crystalloids vs saline for IV fluid administration in critically ill patients
- RABBIT 2 – use of basal bolus insulin vs sliding scale insulin in non-critically ill hospitalized patients with T2DM
- AVERT – use of Apixaban to prevent VTE in ambulatory high risk cancer patients, CASSINI – use of use of Rivaroxaban to prevent VTE in high risk ambulatory cancer patients
- PREVENT – use of adjunct SCDs vs pharmacologic anti-coagulation alone for the prevention of DVTs
PROMISE trial – CTA vs functional testing for CAD - SCOT Heart – 5 year follow-up data on CTA + functional testing vs functional testing alone for CAD
- REDUCE IT – Icosapent Ethyl to reduce TG levels and decrease CV events
- POEM – oral antibiotics for left-sided endocarditis
- ASPREE – aspirin for reduction of mortality and improvement of disability-free survival
- CANVAS and EMPA-REG – SGLT2 inhibitors for CV event rate reduction
- PARADIGM-HF – the use ARB-neprilysin inhibitor for HFrEF
- FOURIER – use of PCSK9 inhibitors for CV event reduction
